465 related articles for article (PubMed ID: 21743374)
1. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
3. The impact of CYP2D6 genetic polymorphisms on postoperative morphine consumption.
Candiotti KA; Yang Z; Rodriguez Y; Crescimone A; Sanchez GC; Takacs P; Medina C; Zhang Y; Liu H; Gitlin MC
Pain Med; 2009; 10(5):799-805. PubMed ID: 19523031
[TBL] [Abstract][Full Text] [Related]
4. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
Zahari Z; Ismail R
Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
[TBL] [Abstract][Full Text] [Related]
5. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
[TBL] [Abstract][Full Text] [Related]
7. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
8. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room.
Yang Z; Yang Z; Arheart KL; Morris R; Zhang Y; Rodriguez Y; Song C; Gitlin MC; Candiotti KA
Pain Med; 2012 Apr; 13(4):604-9. PubMed ID: 22497725
[TBL] [Abstract][Full Text] [Related]
10. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
Stauble ME; Moore AW; Langman LJ; Boswell MV; Baumgartner R; McGee S; Metry J; Jortani SA
Clin Chim Acta; 2014 Feb; 429():26-9. PubMed ID: 24269714
[TBL] [Abstract][Full Text] [Related]
11. CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin?
He YJ; Brockmöller J; Schmidt H; Roots I; Kirchheiner J
J Anal Toxicol; 2008 Mar; 32(2):178-82. PubMed ID: 18334103
[TBL] [Abstract][Full Text] [Related]
12. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study.
Madadi P; Ross CJ; Hayden MR; Carleton BC; Gaedigk A; Leeder JS; Koren G
Clin Pharmacol Ther; 2009 Jan; 85(1):31-5. PubMed ID: 18719619
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
16. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
[TBL] [Abstract][Full Text] [Related]
17. Complicated pain management in a CYP450 2D6 poor metabolizer.
Foster A; Mobley E; Wang Z
Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
[TBL] [Abstract][Full Text] [Related]
18. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype.
Mikus G; Trausch B; Rodewald C; Hofmann U; Richter K; Gramatté T; Eichelbaum M
Clin Pharmacol Ther; 1997 Apr; 61(4):459-66. PubMed ID: 9129563
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
20. Wither codeine?
Tremlett MR
Paediatr Anaesth; 2013 Aug; 23(8):677-83. PubMed ID: 23668390
[No Abstract] [Full Text] [Related]
[Next] [New Search]
